Page
%P
-
Article
Open AccessIncidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting....